Payment overview · 2025
General Payments
$154.44
7 reported records · 5 companies
Healthcare provider profile · identity verified
Cynthia L Sumner, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FORT GAINES, GA · NPI 1235181884
Verified facts
What the public records show
CMS Open Payments records show Cynthia L Sumner, MD received $154.44 in general payments during 2025 across 7 reported records.
Novo Nordisk Inc accounted for 31.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.79 | 31.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.17 | 24.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.96 | 16.2% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $23.74 | 15.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.78 | 12.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $154.44 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.79 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.79 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $37.17 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.96 | 1 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 493 | 200 |
| Atorvastatin Calcium | Atorvastatin Calcium | 336 | 146 |
| Losartan Potassium | Losartan Potassium | 326 | 145 |
| Amlodipine Besylate | Amlodipine Besylate | 298 | 138 |
| Gabapentin | Gabapentin | 284 | 100 |
| Alprazolam | Alprazolam | 275 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 274 | 124 |
| Lisinopril | Lisinopril | 236 | 102 |
| Montelukast Sodium | Montelukast Sodium | 227 | 84 |
| Omeprazole | Omeprazole | 194 | 80 |
| Pravastatin Sodium | Pravastatin Sodium | 184 | 79 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 70 |
| Potassium Chloride | Potassium Chloride | 154 | 79 |
| Sertraline Hcl | Sertraline Hcl | 142 | 46 |
| Allopurinol | Allopurinol | 137 | 46 |
| Famotidine | Famotidine | 135 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 131 | 62 |
| Tramadol Hcl | Tramadol Hcl | 131 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 129 | 59 |
| Ezetimibe | Ezetimibe | 128 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 126 | 55 |
| Simvastatin | Simvastatin | 122 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 120 | 36 |
| Temazepam | Temazepam | 116 | 35 |
| Meloxicam | Meloxicam | 115 | 46 |
| Glimepiride | Glimepiride | 113 | 41 |
| Metformin Hcl | Metformin Hcl | 113 | 47 |
| Januvia | Sitagliptin Phosphate | 111 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 106 | 46 |
| Eliquis | Apixaban | 100 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 100 | 45 |
| Lorazepam | Lorazepam | 98 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 48 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 95 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 46 |
| Trazodone Hcl | Trazodone Hcl | 94 | 40 |
| Furosemide | Furosemide | 93 | 49 |
| Ropinirole Hcl | Ropinirole Hcl | 93 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 89 | 32 |
| Mounjaro | Tirzepatide | 88 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 32 |
| Donepezil Hcl | Donepezil Hcl | 86 | 28 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 83 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 77 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 28 |
| Prednisone | Prednisone | 77 | 56 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 32 |
| Celecoxib | Celecoxib | 74 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 74 | 36 |
| Ondansetron Hcl | Ondansetron Hcl | 74 | 29 |
| Myrbetriq | Mirabegron | 68 | 19 |
| Buspirone Hcl | Buspirone Hcl | 65 | 25 |
| Glipizide Er | Glipizide | 61 | 26 |
| Ibandronate Sodium | Ibandronate Sodium | 60 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 57 | 21 |
| Meclizine Hcl | Meclizine Hcl | 56 | 23 |
| Memantine Hcl | Memantine Hcl | 56 | 16 |
| Xarelto | Rivaroxaban | 54 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 22 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | 16 |
| Fluconazole | Fluconazole | 50 | 33 |
| Azithromycin | Azithromycin | 49 | 38 |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | 21 |
| Solifenacin Succinate | Solifenacin Succinate | 47 | 17 |
| Clonidine Hcl | Clonidine Hcl | 46 | 16 |
| Eszopiclone | Eszopiclone | 46 | 15 |
| Carvedilol | Carvedilol | 45 | 21 |
| Ozempic | Semaglutide | 45 | 14 |
| Promethazine Hcl | Promethazine Hcl | 45 | 11 |
| Topiramate | Topiramate | 45 | 14 |
| Pregabalin | Pregabalin | 44 | 20 |
| Synthroid | Levothyroxine Sodium | 44 | 17 |
| Atenolol | Atenolol | 42 | 15 |
| Bupropion Xl | Bupropion Hcl | 41 | 17 |
| Colesevelam Hcl | Colesevelam Hcl | 41 | 12 |
| Glipizide | Glipizide | 41 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 32 |
| Nystatin | Nystatin | 36 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Nifedipine Er | Nifedipine | 35 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 34 | 12 |
| Baclofen | Baclofen | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 21 |
| Torsemide | Torsemide | 33 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | 13 |
| Sucralfate | Sucralfate | 32 | 17 |
| Vascepa | Icosapent Ethyl | 32 | suppressed |
| Clonazepam | Clonazepam | 31 | 13 |
| Fenofibrate | Fenofibrate | 31 | 18 |
| Galantamine Er | Galantamine Hbr | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 15 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 31 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | 13 |
| Ramipril | Ramipril | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 19 |
| Colchicine | Colchicine | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Primidone | Primidone | 27 | 14 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 26 | suppressed |
| Estradiol | Estradiol | 26 | 15 |
| Gemfibrozil | Gemfibrozil | 26 | 11 |
| Jardiance | Empagliflozin | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | 14 |
| Amoxicillin | Amoxicillin | 25 | 21 |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Sotalol | Sotalol Hcl | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | 13 |
| Spironolactone | Spironolactone | 23 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | 12 |
| Valsartan | Valsartan | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | 12 |
| Carisoprodol | Carisoprodol | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Nexium | Esomeprazole Magnesium | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 13 |
| Finasteride | Finasteride | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | 11 |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $154.44 · 7 records | Novo Nordisk Inc | Ambulatory Monitoring & Diagnostics Undivided, Dexcom G6 Transmitter, Ozempic, PAXLOVID, Rybelsus, TRELEGY ELLIPTA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error